IN8bio stock in focus after 20.9-month glioblastoma survival data
Published on 11/17/2026 at 00:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpdated clinical data strengthen pipeline focus
- IN8bio presented updated results from its INB-200 and INB-400 programs for newly diagnosed glioblastoma.
- The analysis covered 17 patients treated at four cancer centers.
- The company reported no observed cytokine release syndrome, ICANS, major infections or treatment-related serious adverse events in the studies.
IN8bio presented updated clinical data from its INB-200 and INB-400 programs for newly diagnosed glioblastoma on November 16, 2026. The findings were announced in connection with an oral presentation at the Society for Neuro-Oncology annual meeting in Philadelphia and detailed by BioSpace.
Across the two studies, patients receiving repeat doses of the company's drug-resistant gamma-delta T cells achieved median overall survival of 20.9 months, compared with 13.2 months for the standard-of-care group. Median progression-free survival was 13.0 months versus 6.6 months for standard of care. Seven of 14 repeat-dose patients were alive at two years, compared with one of 10 patients in the control group.
Safety profile remains central
The release said the therapy produced no observed cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, major infections or treatment-related serious adverse events with up to six repeat doses. No treatment-related deaths were reported. The analysis included 17 patients treated at four cancer centers, with data as of October 30, 2026.
IN8bio stock traded at 0.70 euros on Lang & Schwarz at 23:00 CET on Monday, November 16. The company's Nasdaq-listed shares had closed at 0.82 US dollars on the same day, according to the company's primary-market quotation.
Clinical-stage biotech pipeline
IN8bio is a New York-based clinical-stage biotechnology company developing gamma-delta T cell therapies and gamma-delta T cell engagers for cancer and autoimmune diseases. Its pipeline includes INB-200 and INB-400 for glioblastoma, INB-100 for high-risk leukemia and the INB-600 engager platform. The company remains focused on advancing early-stage programs rather than commercial products.
IN8bio company facts
- Company: IN8bio, Inc.
- ISIN: US45674E2081
- Ticker: INAB
- Home exchange: Nasdaq
- Lang & Schwarz quote: 0.70 euros at 23:00 CET on November 16, 2026
- Sector: Healthcare
- Industry: Biotechnology
US equities remain the relevant market environment for IN8bio, alongside the S&P 500.
More news and analyses on IN8bio stock are available here.
